" class="no-js "lang="en-US"> Steve Rotheram - Medtech Alert
Thursday, September 11, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Steve Rotheram

Steve Rotheram

About Steve Rotheram

Rotheram was born in Liverpool in 1961, the son of Harry Rotheram, a Kirkby factory forklift driver and Labour councillor, and Dorothy, née Phillips. He was one of eight children. His parents’ marriage broke up when Rotheram was in his teens, with Rotheram citing his father’s absences due to politics as part of the cause. His secondary education was at Ruffwood School in Kirkby.

Related Story

Company Releases

 New £12.7M Centre of Excellence in Emerging Digital Technologies Officially Opens | Pharmtech Focus

New £12.7M Centre of Excellence in Emerging Digital Technologies Officially Opens

May 24 2022

The University of Liverpool’s Digital Innovation Facility (DIF), a £12.7 million Centre of Excellence in […]